When is JAK2 (Janus kinase 2) testing indicated and what are the first‑line treatment options for polycythemia vera, essential thrombocythemia, and primary myelofibrosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board

Educational purpose only • Exercise caution as content is pending human review

Article Review Status

Submitted

Under Review

Approved

Last updated: February 19, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Related Questions

What are the next steps for a patient in their late 50s with symptoms suggestive of a myeloproliferative neoplasm (MPN) but a negative JAK2 Val617Phe variant analysis result?

Does Janus kinase 2 (JAK2) cause macrocytosis?

What is the treatment approach for a patient with a myeloproliferative neoplasm (MPN) and a JAK2 (Janus kinase 2) mutation?

How should I evaluate and manage a patient with a positive Janus kinase 2 (JAK2) V617F mutation and persistent thrombocytosis?

When is JAK2 V617F testing indicated and how is it utilized in the diagnosis and management of suspected myeloproliferative neoplasms?

Can escitalopram and bupropion be co‑prescribed safely in an adult patient with depression?

Is nebulized tranexamic acid contraindicated in a patient with an active pulmonary embolism?

In an adult febrile neutropenic patient (absolute neutrophil count <500 cells/µL) undergoing chemotherapy, how many days should levofloxacin be administered?

What do target cells on a peripheral blood smear indicate and how should they be evaluated and managed in a patient with anemia?

What are the standard dosing, schedules, major toxicities, and alternative options for the following adult solid‑tumor regimens: cisplatin + 5‑fluorouracil (3 cycles); cisplatin + paclitaxel (3 cycles); nimotuzumab (anti‑EGFR monoclonal antibody) + carboplatin + gemcitabine (1 cycle); gemcitabine (1 cycle); gemcitabine + carboplatin + Theracim (1 cycle); gemcitabine + carboplatin (cycle 2B); nimotuzumab + carboplatin (4 cycles); paclitaxel + tislelizumab (PD‑1 inhibitor) (6 cycles); and tislelizumab (4 cycles)?

What are the clinical indications and uses of the JAK2 (Janus kinase 2) assay?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.